Helicos BioSciences (HLCS) Reports Q2 Loss of $0.57, Misses by 1c
More News related to HLCS
- Helicos BioSciences (HLCS) to Cut Workforce by 30%
- Helicos BioSciences (HLCS) Names Lowy as CEO
- Helicos BioSciences Corporation Realigns Senior Management Team
- Helicos Launches Open Access Web Site With Microbial Genome Data
- Helicos BioSciences (HLCS) Reports Mixed Q3 Results
Helicos BioSciences Corporation (NASDAQ: HLCS) reports a Q2 loss of $0.57, 1 cent lower than the analyst estimate of ($0.56). Revenues for the quarter were $251K, versus the consensus of $320K.
Helicos BioSciences Corporation, a life sciences company, engages in the development of genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets.
Related Categories
EarningsStocks Mentioned
+0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
